comparemela.com
Home
Live Updates
Urovant Sciences, Inc.: Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting : comparemela.com
Urovant Sciences, Inc.: Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium
Related Keywords
United States
,
Washington
,
Seattle
,
Americans
,
American
,
Sumitovant Biopharma
,
Sumitomo Pharma
,
Maya Frutiger
,
Alana Darden Powell
,
David Staskin
,
Jeffrey Frankel
,
Drug Administration
,
American Urological Association
,
Urovant Sciences Gmb
,
Seattle Urology Research Center
,
Corporate Communications
,
Tufts University School Of Medicine
,
Us Public Health
,
Urovant Sciences
,
Sumitovant Biopharma Ltd
,
Head Of Corporate Communications
,
Patient Global Impression
,
New Orleans
,
Sef Kurstjens
,
Executive Vice President
,
Chief Medical Officer
,
Medical Director
,
Term Efficacy
,
Overactive Bladder
,
Associate Professor
,
Tufts University School
,
Term Patient Reported Outcomes
,
Product Information
,
Urovant Sciences Gmbh
,
Darden Powell
,
Urovant
,
Ciences
,
Presents
,
Data
,
Rom
,
Mpowur
,
Study
,
Dvancing
,
Knowledge
,
Treatment
,
Overactive
,
Ladder
,
022
,
Irological
,
Association
,
Meeting
,
comparemela.com © 2020. All Rights Reserved.